Mineralys Therapeutics (NASDAQ:MLYS) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Mineralys Therapeutics (NASDAQ:MLYS) from a sell rating to a hold rating in a report published on Sunday.

Several other analysts have also recently weighed in on MLYS. Stifel Nicolaus boosted their price objective on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Jefferies Financial Group reaffirmed a “hold” rating and set a $30.00 target price on shares of Mineralys Therapeutics in a report on Friday. HC Wainwright set a $56.00 price target on Mineralys Therapeutics and gave the company a “buy” rating in a research report on Tuesday, March 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Thursday, January 22nd. Finally, Bank of America boosted their price target on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a research report on Friday. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Mineralys Therapeutics has an average rating of “Moderate Buy” and an average target price of $49.14.

Mineralys Therapeutics Stock Down 3.0%

NASDAQ MLYS opened at $26.19 on Friday. The company has a market cap of $2.16 billion, a price-to-earnings ratio of -11.05 and a beta of 0.57. Mineralys Therapeutics has a twelve month low of $10.44 and a twelve month high of $47.65. The business’s fifty day moving average is $30.45 and its 200 day moving average is $35.65.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.17. On average, research analysts anticipate that Mineralys Therapeutics will post -4.23 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Adam Scott Levy sold 10,758 shares of the stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $32.14, for a total transaction of $345,762.12. Following the transaction, the chief financial officer owned 8,638 shares of the company’s stock, valued at $277,625.32. This represents a 55.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider David Malcom Rodman sold 192,715 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $35.02, for a total value of $6,748,879.30. Following the completion of the sale, the insider directly owned 61,804 shares of the company’s stock, valued at $2,164,376.08. This trade represents a 75.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 342,919 shares of company stock worth $11,755,439. Company insiders own 33.24% of the company’s stock.

Institutional Trading of Mineralys Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC purchased a new position in Mineralys Therapeutics during the 1st quarter worth $550,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Mineralys Therapeutics by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after buying an additional 702 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Mineralys Therapeutics by 166.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company’s stock worth $4,739,000 after buying an additional 186,480 shares in the last quarter. Woodline Partners LP purchased a new position in shares of Mineralys Therapeutics in the 1st quarter worth approximately $757,000. Finally, Profund Advisors LLC purchased a new position in shares of Mineralys Therapeutics in the 2nd quarter worth approximately $164,000. 84.46% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Mineralys Therapeutics

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: NDA accepted by FDA and PDUFA set (Dec. 22, 2026) for lorundrostat — formal regulatory review underway, which de-risks timing for potential approval and commercialization. GlobeNewswire: Q4 results & NDA acceptance
• Positive Sentiment: Q4 results surprised to the upside — reported EPS of ($0.40) vs. consensus ($0.57), suggesting operational execution beat expectations and reducing near-term downside to estimates. MarketBeat: Q4 earnings summary
• Positive Sentiment: Management is actively preparing for launch and payer engagement ahead of the regulatory decision — signaling commercialization planning and market-access work that could speed uptake if approved. Seeking Alpha: Launch & payer engagement
• Neutral Sentiment: Conference call and transcript provide management’s roadmap and data context (Q4 call reviewed NDA strategy, clinical data and next steps); useful for modeling but not a surprise item. Seeking Alpha: Earnings call transcript
• Neutral Sentiment: Press coverage highlights steady progress with FDA interactions and public messaging; these articles reiterate facts rather than deliver new catalysts. Yahoo Finance: FDA progress TipRanks: NDA acceptance overview
• Negative Sentiment: Critical commentary warns of potential interference from larger pharma interests that could complicate the approval or market dynamics — introduces regulatory and competitive risk that can pressure shares. Seeking Alpha: Concerns over big pharma pressure

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.